Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection

This study has been completed.
Sponsor:
Collaborator:
Bill and Melinda Gates Foundation
Information provided by (Responsible Party):
Albert B. Sabin Vaccine Institute
ClinicalTrials.gov Identifier:
NCT00120081
First received: July 7, 2005
Last updated: July 20, 2012
Last verified: July 2012

July 7, 2005
July 20, 2012
April 2005
September 2006   (final data collection date for primary outcome measure)
Safety and tolerability of three different doses of the Na-ASP-2 hookworm vaccine in healthy volunteers [ Time Frame: For the duration of the study ] [ Designated as safety issue: Yes ]
To evaluate the safety and tolerability of three different doses of the Na-ASP-2 hookworm vaccine in healthy volunteers.
Complete list of historical versions of study NCT00120081 on ClinicalTrials.gov Archive Site
To determine the immunogenicity, both humoral and cellular, of the vaccine at specified time points following vaccination [ Time Frame: 2, 8, 10, 16, 18, 24, and 48 weeks after the first injection ] [ Designated as safety issue: No ]
To determine the immunogenicity, both humoral and cellular, of the vaccine at specified time points.
Not Provided
Not Provided
 
Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection
Phase 1, Single-Center, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study to Compare the Safety, Tolerability, and Immunogenicity of Three Intramuscular Administrations of Na-ASP-2 Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection

The primary objective of this clinical trial is to determine the safety and tolerability of the Na-ASP-2 Hookworm Vaccine in healthy subjects following the administration of 3 intramuscular (IM) injections of the vaccine over 16 weeks using 3 different doses. The secondary objective is to make a preliminary evaluation of the immunogenicity of each of the 3 doses of the vaccine in healthy volunteers.

There is an urgent need for new tools to control human hookworm infection and to reduce its burden of disease in developing countries. This is especially true for children and women of reproductive age who represent populations that are highly vulnerable to the effects of hookworm disease. Up to 65,000 deaths annually have been attributed to human hookworm infection. However, the mortality estimates of hookworm pale in comparison to global disease burden estimates.

The primary approach to hookworm control worldwide has been the frequent and periodic use of benzimidazole anthelminthics for school-age children. However, school-based anthelminthic chemotherapy programs miss populations highly vulnerable to hookworm, including adolescent and adult women. In addition, high rates of hookworm re-infection occur within 4-12 months following anthelminthic chemotherapy, and there is evidence for diminished efficacy of benzimidazoles with frequent and periodic use, possibly because of emerging drug resistance. These concerns have prompted interest in developing alternative tools for hookworm control. Vaccination to prevent high intensity hookworm infection would alleviate the public health deficiencies of drug treatment alone.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Hookworm Infection
  • Biological: Na-ASP-2/Alhydrogel Hookworm Vaccine
    The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.
  • Biological: Saline placebo
    Inactive saline placebo control
  • Experimental: Low dose
    10 mcg Na-ASP-2/Alhydrogel
    Intervention: Biological: Na-ASP-2/Alhydrogel Hookworm Vaccine
  • Experimental: Medium dose
    50 mcg Na-ASP-2/Alhydrogel
    Intervention: Biological: Na-ASP-2/Alhydrogel Hookworm Vaccine
  • Experimental: High dose
    100 mcg Na-ASP-2/Alhydrogel
    Intervention: Biological: Na-ASP-2/Alhydrogel Hookworm Vaccine
  • Placebo Comparator: Saline placebo
    Saline placebo
    Intervention: Biological: Saline placebo
Bethony JM, Simon G, Diemert DJ, Parenti D, Desrosiers A, Schuck S, Fujiwara R, Santiago H, Hotez PJ. Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 hookworm vaccine in unexposed adults. Vaccine. 2008 May 2;26(19):2408-17. Epub 2008 Mar 11.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
September 2006
September 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy adults 18 to 45 years of age.
  • Signed informed consent.
  • History, physical exam, and laboratory tests indicating good general health obtained prior to the first injection.
  • All females must have a negative pregnancy test (FDA-approved test for β human chorionic gonadotropin [β-HCG]) on the day of the first injection.
  • Serologic tests for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) are negative at screening.
  • All subjects must agree to use an acceptable method of birth control from the start of screening until 2 weeks after the third injection. Acceptable methods for female subjects include hormonal contraceptives, intrauterine device (IUD), diaphragm with spermicide, condoms, abstinence, surgically sterile (hysterectomy), and surgically sterile partner. Acceptable methods for male subjects include surgical sterilization, condoms, partner who uses an acceptable method of birth control, and abstinence.

Exclusion Criteria:

  • Any history of anaphylaxis or allergy to vaccine components or allergy to insect stings, including bee stings.
  • A past or current history of hookworm infection.
  • BMI < 18.0 or > 30.0.
  • Recent (< 72 hours) history of febrile illness at the time of vaccination (temperature > 99.6°F or equivalent).
  • Received any immune globulin or blood product 3 months prior to injection or scheduled within 4 weeks thereafter.
  • Had vaccination with a live virus vaccine within 4 weeks before receipt of the vaccine or scheduled within 4 weeks thereafter.
  • Had vaccination with a killed vaccine, or allergy treatment with antigen injections within 14 days of initial study injection.
  • Received an investigational agent within 4 weeks of initial study injection.
  • Known or suspected impairment of immunologic function including, but not limited to clinically significant liver disease, diabetes mellitus, moderate to severe kidney impairment (creatinine > 1.5), any history of malignancy (except squamous cell or basal cell skin cancer), HIV infection or autoimmune diseases, or concomitant immunosuppressive medication such as glucocorticosteroids.
  • A history of essential hypertension, gastrointestinal abnormalities such as peptic ulcer disease, cardiac (ECG abnormalities), pulmonary, hepatic, renal, pancreatic, or neurologic disease.
  • Taken prescription medications with the exception of subjects on a stable regimen (> 30 days) of: (1) hormone replacement therapy, (2) use of nasal steroids, (3) topical therapy, (4) certain classes of antidepressants (i.e., selective serotonin re-uptake inhibitors), (5) oral contraceptives, (6) nonsteroidal anti-inflammatory agents, or (7) antihistamines or decongestants for seasonal allergies taken as needed.
  • Contraindication to IM injection such as anti-coagulant therapy or thrombocytopenia.
  • Pregnant, nursing, or expecting to conceive during the study.
  • Any history of chronic alcohol or drug abuse or current treatment with any known prescribed or over-the-counter supplements that may be hepatotoxins.
  • Any subject who, in the Investigator's opinion, will be unable to adhere to protocol requirements.
Both
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00120081
SVI-04-01
Yes
Albert B. Sabin Vaccine Institute
Albert B. Sabin Vaccine Institute
Bill and Melinda Gates Foundation
Principal Investigator: Gary Simon, M.D., Ph.D George Washington University
Albert B. Sabin Vaccine Institute
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP